Advertisement

Der Nervenarzt

, Volume 86, Issue 3, pp 291–301 | Cite as

Depressive und Angststörungen bei Krebserkrankungen

  • H.-P. KapfhammerEmail author
Leitthema

Zusammenfassung

Patienten mit Krebserkrankungen weisen eine hohe Rate an komorbiden depressiven und Angststörungen auf, die paradigmatisch in einen komplexen biopsychosozialen Kontext gestellt werden müssen. Bei der Diagnosestellung sind einige konzeptuelle Herausforderungen zu meistern. Die psychischen Komorbiditäten bedeuten nicht nur ein höheres subjektives Leiden, ein reduziertes Coping, mögliche negative Interferenzen mit somatischen Therapien und Rehabilitationen, eine stärker beeinträchtigte Lebensqualität sowie höhere Grade an psychosozialer Behinderung. Sie schließen auch ein höheres somatisches Morbiditäts- und Mortalitätsrisiko im weiteren Verlauf ein. Die vielfältigen psychologischen, psychosozialen, morbogenen und therapiebezogenen Stressoren müssen aufeinander bezogen und auf gemeinsame neurobiologische, v. a. neuroendokrine, neuroinflammatorische Vermittlungsmechanismen hin reflektiert werden. Hierbei sind stets mehrfache psychosomatische, somatopsychische und somatosomatische Effekte zu beachten. Es existieren evidenzbasierte psychotherapeutische und psychopharmakologische Ansätze für eine integrative Behandlung der komorbiden depressiven und Angststörungen.

Schlüsselwörter

Krebs Angststörung Depressive Störung Biopsychosoziales Modell Epidemiologie 

Comorbid depressive and anxiety disorders in patients with cancer

Summary

Patients with cancer face a high risk of comorbid depressive and anxiety disorders that have to be paradigmatically considered within a complex biopsychosocial context. Several conceptual challenges have to be mastered in arriving at a correct clinical diagnosis. Coexistent affective and anxiety disorders in cancer patients include a more dramatic subjective suffering, reduced psychological coping, possible negative interference with somatic treatment and rehabilitation, impaired quality of life and higher grades of psychosocial disability. They may also lead to an overall increased risk of somatic morbidity, a more rapid progression of cancer and a higher cancer-related mortality in the course of the disease. Manifold psychological, psychosocial and existential, cancer and treatment-related stressors have to be considered with respect to common neurobiological, especially neuroendocrine and neuroinflammatory mechanisms. Complex psychosomatic, somatopsychic and somato-somatic effects must always be considered. Evidence-based approaches in psychotherapy and pharmacotherapy exist for the integrative treatment of comorbid depressive and anxiety disorders in cancer.

Keywords

Cancer Anxiety disorder Depressive disorder Biopsychosocial model Epidemiology 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. H.P. Kapfhammer gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Kapfhammer HP (2015) Psychische Störungen bei somatischen Krankheiten. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg) Psychiatrie, Psychosomatik, Psychotherapie, 5. Aufl. Springer, Berlin (im Druck)Google Scholar
  2. 2.
    Levin TT, Alici Y (2010) Anxiety disorders. In: Holland JC, Breitbart W, Paul B. Jacobsen PB (Hrsg) Textbook of psycho-oncology, 2. Aufl. Oxford University Press, Oxford, S 324–331Google Scholar
  3. 3.
    Miller K, Massie MJ (2010) Depressive disorders. In: Holland JC, Breitbart W, Paul B. Jacobsen PB (Hrsg) Textbook of psycho-oncology, 2. Aufl. Oxford University Press, Oxford, S 311–318Google Scholar
  4. 4.
    Li M, Fitzgerald P, Rodin G (2012) Evidence-based treatment of depression in patients with cancer. J Clin Oncol 30:1187–1196CrossRefPubMedGoogle Scholar
  5. 5.
    Tecuta L, Tomba E, Grandi S, Fava GA (2014) Demoralization: a systematic review on its clinical characterization. Psychol Med (Epub ahead of print)Google Scholar
  6. 6.
    Robinson S, Kissane DW, Brooker J, Burney S (2014) A Systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research. J Pain Symptom Manage (Epub ahead of print)Google Scholar
  7. 7.
    Traeger L, Greer JA, Fernandez-Robles C et al (2012) Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol 30:1197–1205CrossRefPubMedGoogle Scholar
  8. 8.
    Kapfhammer HP (2014) Diagnostische Konzeptualisierung von Trauma- und Stressor-bezogenen Störungen im DSM 5. Nervenarzt 85:553–563CrossRefPubMedGoogle Scholar
  9. 9.
    Andersen BL, DeRubeis RJ, Berman BS et al (2014) Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605–1619CrossRefPubMedGoogle Scholar
  10. 10.
    Walker J, Holm Hansen C, Martin P et al (2013) Prevalence of depression in adults with cancer: a systematic review. Ann Oncol 24:895–900CrossRefPubMedGoogle Scholar
  11. 11.
    Mitchell AJ, Chan M, Bhatti H et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174CrossRefPubMedGoogle Scholar
  12. 12.
    Boyes AW, Girgis A, D’Este CA et al (2013) Prevalence and predictors of the short-term trajectory of anxiety and depression in the first year after a cancer diagnosis: a population-based longitudinal study. J Clin Oncol 31:2724–2729CrossRefPubMedGoogle Scholar
  13. 13.
    Mehnert A, Vehling S, Scheffold K et al (2013) Prävalenz von Anpassungsstörung, Akuter und Posttraumatischer Belastungsstörung sowie somatoformen Störungen bei Krebspatienten. Ein systematischer Literaturreview und Metaanalyse. Psychother Psychosom Med Psychol 63:466–472CrossRefPubMedGoogle Scholar
  14. 14.
    Mehnert A, Brähler E, Faller H et al (2014) Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 32:3540–3546CrossRefPubMedGoogle Scholar
  15. 15.
    Kiserud CE, Dahl AA, Loge JH, Fosså SD (2014) Cancer survivorship in adults. Recent Results Cancer Res 197:103–120CrossRefPubMedGoogle Scholar
  16. 16.
    Koch L, Jansen L, Brenner H, Arndt V (2013) Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors – a systematic review of quantitative studies. Psychooncology 22:1–11CrossRefPubMedGoogle Scholar
  17. 17.
    Mitchell AJ, Ferguson DW, Gill J et al (2013) Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol 14:721–732CrossRefPubMedGoogle Scholar
  18. 18.
    Currier MB, Nemeroff CB (2014) Depression as a risk factor for cancer: from pathophysiological advances to treatment implications. Annu Rev Med 65:203–221CrossRefPubMedGoogle Scholar
  19. 19.
    Penninx BW, Guralnik JM, Pahor M et al (1998) Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90:1888–1893CrossRefPubMedGoogle Scholar
  20. 20.
    Gallo JJ, Armenian HK, Ford DE et al (2010) Major depression and cancer: the 13-year follow-up of the Baltimore epidemiologic catchment area sample (United States). Cancer Causes Control 11:751–758CrossRefGoogle Scholar
  21. 21.
    Gross AL, Gallo JJ, Eaton WW (2010) Depression and cancer risk: 24 years of follow-up of the Baltimore Epidemiologic Catchment Area sample. Cancer Causes Control 21:191–199CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Chida Y, Hamer M, Wardle J, Steptoe A (2008) Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 5:466–475CrossRefPubMedGoogle Scholar
  23. 23.
    Lillberg K, Verkasalo PK, Kaprio J et al (2003) Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol 157:415–423CrossRefPubMedGoogle Scholar
  24. 24.
    Hamer M, Chida Y, Molloy GJ (2009) Psychological distress and cancer mortality. J Psychosom Res 66:255–258CrossRefPubMedGoogle Scholar
  25. 25.
    Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115:5349–5361CrossRefPubMedGoogle Scholar
  26. 26.
    Pinquart M, Duberstein PR (2010) Depression and cancer mortality: a meta-analysis. Psychol Med 40:1797–1810CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Hem E, Loge JH, Haldorsen T, Ekeberg Ø (2004) Suicide risk in cancer patients from 1960 to 1999. J Clin Oncol 22:4209–4216CrossRefPubMedGoogle Scholar
  28. 28.
    Rasic DT, Belik SL, Bolton JM et al (2008) Cancer, mental disorders, suicidal ideation and attempts in a large community sample. Psychooncology 17:660–667CrossRefPubMedGoogle Scholar
  29. 29.
    Robson A, Scrutton F, Wilkinson L, MacLeod F (2010) The risk of suicide in cancer patients: a review of the literature. Psychooncology 19:1250–1258CrossRefPubMedGoogle Scholar
  30. 30.
    Breitbart W, Rosenfeld B, Pessin H et al (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 284:2907–2911CrossRefPubMedGoogle Scholar
  31. 31.
    Garssen B (2004) Psychological factors and cancer development: evidence after 30 years of research. Clin Psychol Rev 24:315–338CrossRefPubMedGoogle Scholar
  32. 32.
    Kangas M, Henry JL, Bryant RA (2005) Predictors of posttraumatic stress disorder following cancer. Health Psychol 24:579–585CrossRefPubMedGoogle Scholar
  33. 33.
    Makrilia N, Indeck B, Syrigos K, Saif MW (2009) Depression and pancreatic cancer: a poorly understood link. J Pancreas 10:69–76Google Scholar
  34. 34.
    Miller AH (2009) Norman Cousins Lecture. Mechanisms of cytokine induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 23:149–158CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Lutgendorf SK, Sood AK (2011) Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med 73:724–730CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Haroon E, Raison CL, Miller AH (2012) Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37:137–162CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Aldea M, Craciun L, Tomuleasa C, Crivii C (2014) The role of depression and neuroimmune axis in the prognosis of cancer patients. J BUON 19:5–14PubMedGoogle Scholar
  38. 38.
    Laird BJ, Boyd AC, Colvin LA, Fallon MT (2009) Are cancer pain and depression interdependent? A systematic review. Psychooncology 18:459–464CrossRefPubMedGoogle Scholar
  39. 39.
    Brown LF, Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50:440–447CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Irwin MR (2013) Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Curr Psychiatry Rep 15:404. doi:10.1007/s11920-013-0404-1CrossRefPubMedGoogle Scholar
  41. 41.
    Roxburgh CS, McMillan DC (2014) Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 110:1409–1412CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887–899CrossRefPubMedGoogle Scholar
  43. 43.
    Benton TD, Blume J, Crits-Christoph P et al (2014) Depression and medical illness. In: Charney DS, Skalr P, Buxbaum JD, Nestler EJ (Hrsg) Neurobiology of mental illness, 4. Aufl. Oxford University Press, Oxford, S 496–507Google Scholar
  44. 44.
    Grassi L, Riba M (2012) Clinical psycho-oncology. An international perspective. Wiley-Blackwell, ChichesterGoogle Scholar
  45. 45.
    Faller H, Schuler M, Richard M et al (2013) Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 31:782–793CrossRefPubMedGoogle Scholar
  46. 46.
    Barrera I, Spiegel D (2014) Review of psychotherapeutic interventions on depression in cancer patients and their impact on disease progression. Int Rev Psychiatry 26:31–43CrossRefPubMedGoogle Scholar
  47. 47.
    Fitzgerald P, Li M, Grassi L, Rodin G (2014) Pharmacotherapy of depression in cancer patients. In: Grassi L, Riba M (Hrsg) Psychopharmaclogy in oncology and palliatve care. Springer, Berlin, S 145–161Google Scholar
  48. 48.
    Rayner L, Price A, Evans A et al (2011) Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med 25:36–51CrossRefPubMedGoogle Scholar
  49. 49.
    Laoutidis ZG, Mathiak K (2013) Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry 13:140. doi:10.1186/1471-244X-13-140CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Miguel C, Albuquerque E (2011) Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology 88:333–339CrossRefPubMedGoogle Scholar
  51. 51.
    Grassi L, Nanni MG, Uchitomi Y, Riba M (2011) Pharmacotherapy in people with cancer. In: Kissane DW, Maj M, Sartorius N (Hrsg) Depression and cancer. Wiley-Blackwell, Chichester, S 151–176Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Klinik für PsychiatrieMedizinische Universität GrazGrazÖsterreich

Personalised recommendations